Expand BMY Menu
BMY MENU

BMY Latest Press Releases

-- July 28, 2025 --

Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients Business Wire 4:16 PM

-- July 25, 2025 --

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development Business Wire 6:59 AM

-- July 21, 2025 --

Bristol Myers Squibb's Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally Business Wire 6:59 AM

-- July 18, 2025 --

Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia Business Wire 6:59 AM

-- July 17, 2025 --

Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis (apixaban) Option Business Wire 6:59 AM

-- June 26, 2025 --

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels Business Wire 10:05 PM

-- June 17, 2025 --

Bristol Myers Squibb Announces Dividend Business Wire 4:16 PM

-- June 16, 2025 --

Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel) Business Wire 6:59 AM

-- June 12, 2025 --

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD Agents and BCL6 Ligand-Directed Degrader at EHA 2025 Business Wire 6:59 AM
Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025 Business Wire 6:45 AM

-- June 11, 2025 --

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis Business Wire 6:59 AM

-- June 10, 2025 --

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties Globe Newswire 5:55 PM

-- June 2, 2025 --

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types Globe Newswire 6:45 AM
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types Business Wire 6:45 AM

-- May 28, 2025 --

Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference Business Wire 6:59 AM
Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo (nivolumab) Across Multiple Solid Tumor Indications Business Wire 6:55 AM

-- May 22, 2025 --

Bristol Myers Squibb to Present Data at ASCO 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline Business Wire 5:05 PM

-- May 21, 2025 --

Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference Business Wire 6:59 AM

-- May 16, 2025 --

Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression =1% Business Wire 6:59 AM

-- May 6, 2025 --

Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Business Wire 6:59 AM

-- April 24, 2025 --

Bristol Myers Squibb Reports First Quarter Financial Results for 2025 Business Wire 6:59 AM

-- April 22, 2025 --

Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia Business Wire 4:15 PM

-- April 17, 2025 --

U.S. Food and Drug Administration Updates CAMZYOS (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications Business Wire 8:21 PM

-- April 16, 2025 --

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT Business Wire 5:16 PM

-- April 15, 2025 --

Optellum Announces Agreement with Bristol Myers Squibb to Leverage AI to Boost Early Lung Cancer Diagnosis PRNewswire 8:00 AM

-- April 14, 2025 --

Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial Business Wire 4:15 PM

-- April 11, 2025 --

U.S. Food and Drug Administration Approves Opdivo (nivolumab) plus Yervoy (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma Business Wire 3:49 PM

-- April 8, 2025 --

U.S. Food and Drug Administration Approves Opdivo (nivolumab) plus Yervoy (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1 Business Wire 3:36 PM

-- April 4, 2025 --

Viz.ai Wins 2025 Edison Award for Machine Learning Innovation for the Third Consecutive Year Business Wire 8:24 AM

-- March 28, 2025 --

Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1... Business Wire 8:53 AM
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo (nivolumab) Across Multiple Solid Tumor Indications Business Wire 8:00 AM

-- March 27, 2025 --

Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements Globe Newswire 8:30 AM

-- March 26, 2025 --

Four New Studies Demonstrate that Viz.ai Finds New Patients with Hypertrophic Cardiomyopathy Earlier When Embedded into the Clinical Workflow Business Wire 9:24 AM

-- March 20, 2025 --

Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer Business Wire 8:00 AM

-- March 14, 2025 --

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT Business Wire 11:24 AM
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma Business Wire 6:59 AM

-- March 13, 2025 --

Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025 Business Wire 6:59 AM

-- March 11, 2025 --

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc. PRNewswire 3:31 PM

-- March 10, 2025 --

2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb Business Wire 10:17 PM

-- March 8, 2025 --

Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis Business Wire 9:01 AM

-- March 7, 2025 --

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma Business Wire 6:59 AM

-- March 4, 2025 --

Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb ACCESS Newswire 1:45 AM

-- March 3, 2025 --

Bristol Myers Squibb Announces Dividend Business Wire 4:16 PM